SOHO 2025
Lisaftoclax Regimens Effective in Plasma Cell Disorders
Lisaftoclax, an investigational BCL2 inhibitor, in combination with pomalidomide/dexamethasone (Pd) or daratumumab/lenalidomide/dexamethasone (DRd) led to improved outcomes for patients with relapsed ...
Cutaneous T-Cell Lymphoma: Use of Durvalumab Alone or With Lenalidomide Under Study in Phase II Trial
In a randomized phase II trial, Christiane Querfeld, MD, PhD, and colleagues investigated the effects of a PD-L1–blocking strategy for targeting both the innate and adaptive immune systems in cutaneou...
Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia
Treatment with obecabtagene autoleucel was the focus of the phase Ib/II multicenter FELIX study of more than 100 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).1 The init...
Bijal Shah, MD, on CAR T-Cell Therapy in ALL
Bijal Shah, MD, of Moffitt Cancer Center, summarizes his presentation on the role of chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia (ALL), touching on its use in the f...
Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia
In a phase I, first-in-human trial of nearly 50 patients with relapsed or refractory B-cell malignancies, the orally administered, small molecule degrader bexobrutideg (NX-5948) was reported to be wel...
Nicholas J. Short, MD: Focus on TP53-Mutated ALL
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses TP53 abnormalities in acute lymphoblastic leukemia (ALL), which are uncommon in pediatric patients but may occur ...
Naval G. Daver, MD, and Uma Borate, MBBS, Debate Lower-Intensity Regimens in AML
Naval G. Daver, MD, of The University of Texas MD Anderson Cancer Center, and Uma Borate, MBBS, of The Ohio State University Comprehensive Cancer Center, give highlights of a lively debate they engage...
Michael J. Mauro, MD, on the ENABLE Study in Heavily Pretreated Patients With CML
Michael J. Mauro, MD, of Memorial Sloan Kettering Cancer Center, reviews findings from the phase Ia/Ib ENABLE study, which evaluated ELVN-001, a highly selective, active-site inhibitor designed to tar...
Nirav N. Shah, MD, MSHP, on a BTK Degrader in Relapsed or Refractory CLL
Nirav N. Shah, MD, MSHP, of the Medical College of Wisconsin, presents results from a phase Ia study of bexobrutideg, a Bruton’s tyrosine kinase (BTK) degrader. The agent was tested in a heavily pretr...
Farhad Ravandi, MD, on AML: Highlights of Ongoing Research
Farhad Ravandi, MD, provides an overview of acute myeloid leukemia (AML) research highlighted in a session at SOHO, including data on menin inhibitors in NPM1-mutated disease; FLT3 inhibitors in FLT3-...
Elias Jabbour, MD, on CAR T-Cell Therapy for Adult Patients With Relapsed/Refractory B-Cell ALL
Elias Jabbour, MD, discusses long-term findings and predictors of sustained remission among adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who did not undergo a stem...
